Paula Gardiner

Paula Gardiner

Auto-generated profile, based on publicly available information

Paula Gardiner

Department of Family Medicine and Community Health, University of Massachusetts Chan Medical School, Worcester, MA, United States

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Drug Safety
Verified
Journal Article
Closed access
PDF file
DSDandapantula N. Sarma
Dandapantula N. Sarma
MBMarilyn L. Barrett
Marilyn L. Barrett
MCMary L. Chavez
Mary L. Chavez
PGPaula Gardiner
Paula Gardiner
RKRichard Ko
Richard Ko
TDTieraona Low Dog
Tieraona Low Dog

1 December 2008 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MMMerry-K. Moos
Merry-K. Moos
ADAnne L. Dunlop
Anne L. Dunlop
Brian JackBrian Jack
Brian Jack
LNLauren Nelson
Lauren Nelson
DCDean V. Coonrod
Dean V. Coonrod
PGPaula M. Gardiner
Paula M. Gardiner

1 September 2017 in Patient Education and Counseling
Verified
Journal Article
Closed access
PGPaula M. Gardiner
Paula M. Gardiner
KMKelly D. McCue
Kelly D. McCue
LNLily M. Negash
Lily M. Negash
TCTeresa Cheng
Teresa Cheng
LWLaura F White
Laura F White
TBTimothy W. Bickmore
Timothy W. Bickmore

27 July 2011 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
RMRobin J. Marles
Robin J. Marles
MBMarilyn L. Barrett
Marilyn L. Barrett
JBJoanne Barnes
Joanne Barnes
MCMary L. Chavez
Mary L. Chavez
PGPaula Gardiner
Paula Gardiner
JGJames Griffiths
James Griffiths
The Dietary Supplements Information Expert Committee (DSI-EC) of the United States Pharmacopeial Convention (USP) reviews the safety of dietary supplements and dietary supplement ingredients for the purpose of determining whether they should be admitted as quality monographs into the United States Pharmacopeia and National Formulary (USP–NF). The United States Food and Drug Administration (FDA) has enforcement authority to pursue a misbranding action in those instances where a dietary supplement product indicates that it conforms to USP standards but fails to so conform. Recently DSI-EC undertook a safety evaluation of spirulina, a widely used dietary ingredient. DSI-EC reviewed information from human clinical trials, animal studies, and regulatory and pharmacopeial sources and analyzed 31 adverse event reports regarding spirulina to assess potential health concerns. At the conclusion of this review, DSI-EC assigned a Class A safety rating for Spirulina maxima and S. platensis, thereby permitting the admission of quality monographs for these dietary supplement ingredients in USP–NF. DSI-EC continually monitors reports concerning the safety of dietary supplements and dietary supplement ingredients for which USP dietary supplement monographs are developed. The DSI-EC may revisit the safety classification of spirulina as new information on this dietary ingredient becomes available.

1 July 2009 in Academic Pediatrics
Verified
Journal Article
Closed access
GBGurjeet S. Birdee
Gurjeet S. Birdee
GYGloria Y. Yeh
Gloria Y. Yeh
PWPeter M. Wayne
Peter M. Wayne
RPRussell S. Phillips
Russell S. Phillips
RDRoger B. Davis
Roger B. Davis
PGPaula Gardiner
Paula Gardiner

1 July 2008 in Menopause
Verified
Journal Article
Closed access
GMGail B. Mahady
Gail B. Mahady
TDTieraona Low Dog
Tieraona Low Dog
MBMarilyn L. Barrett
Marilyn L. Barrett
MCMary L. Chavez
Mary L. Chavez
PGPaula Gardiner
Paula Gardiner
DSDandapantula N. Sarma
Dandapantula N. Sarma
Black cohosh [Actaea racemosa L., formerly Cimicifuga racemosa (L.) Nutt.] is a botanical used mainly for the management of menopausal symptoms. Recently, regulatory agencies in Australia, Canada, and the European Union have released statements regarding the "potential association" between black cohosh and hepatotoxicity. In response, the Dietary Supplement Information Expert Committee of the US Pharmacopeia's Council of Experts reviewed safety information for black cohosh products. The Expert Committee analyzed information from human clinical case reports, adverse event reports, animal pharmacological and toxicological data, historical use, regulatory status, and contemporaneous extent of use. Reports were obtained from diverse sources, including the European Medicines Agency, Health Canada, the Australian Therapeutic Goods Administration, and the US Food and Drug Administration. Case reports pertaining to liver damage were evaluated according to the Naranjo causality algorithm scale. Thirty nonduplicate reports on use of black cohosh products concerning liver damage were analyzed. All the reports of liver damage were assigned possible causality, and none were probable or certain causality. The clinical pharmacokinetic and animal toxicological information did not reveal unfavorable information about black cohosh. Based on this safety review, the Dietary Supplement Information Expert Committee determined that black cohosh products should be labeled to include a cautionary statement. This is a change from the Expert Committee's decision of 2002, which required no such statement. With this decision, the US Pharmacopeia's Botanical Expert Committee may develop monographs for black cohosh, and the US Pharmacopeia may offer its verification programs to dietary supplement ingredient and product manufacturers.